297 related articles for article (PubMed ID: 36742308)
1. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.
Cui X; Wang F; Liu C
Front Immunol; 2023; 14():1062045. PubMed ID: 36742308
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
3. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
4. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
5. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model.
Görtz GE; Moshkelgosha S; Jesenek C; Edelmann B; Horstmann M; Banga JP; Eckstein A; Berchner-Pfannschmidt U
Endocrinology; 2016 Oct; 157(10):3771-3778. PubMed ID: 27552248
[TBL] [Abstract][Full Text] [Related]
7. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Kumar S; Coenen M; Iyer S; Bahn RS
Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
[TBL] [Abstract][Full Text] [Related]
8. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
9. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
Neumann S; Krieger CC; Gershengorn MC
Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
Khoo TK; Bahn RS
Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
[TBL] [Abstract][Full Text] [Related]
11. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
12. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Bahn RS
Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
[TBL] [Abstract][Full Text] [Related]
13. Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors.
Marcus-Samuels B; Krieger CC; Boutin A; Kahaly GJ; Neumann S; Gershengorn MC
Thyroid; 2018 May; 28(5):650-655. PubMed ID: 29631510
[TBL] [Abstract][Full Text] [Related]
14. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
15. Modulating TSH Receptor Signaling for Therapeutic Benefit.
Krause G; Eckstein A; Schülein R
Eur Thyroid J; 2020 Dec; 9(Suppl 1):66-77. PubMed ID: 33511087
[TBL] [Abstract][Full Text] [Related]
16. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
[No Abstract] [Full Text] [Related]
17. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.
Krieger CC; Neumann S; Place RF; Marcus-Samuels B; Gershengorn MC
J Clin Endocrinol Metab; 2015 Mar; 100(3):1071-7. PubMed ID: 25485727
[TBL] [Abstract][Full Text] [Related]
18. Comparison of orbital fibroblasts from Graves' ophthalmopathy and healthy control.
Wu Y; Zhang J; Deng W; Mo C; Liang Y; Huang K; Xu F; Tang F
Heliyon; 2024 Apr; 10(7):e28397. PubMed ID: 38571651
[TBL] [Abstract][Full Text] [Related]
19. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.
Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
